Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Continuous Intercostal Nerve Blocks for Multiple Rib Fractures
NCT05642026Phase 4Recruiting
- Start
- Sep 2025
- Primary completion
- Feb 2027
- Modality
- Targeted Liposomes, Stealth (PEGylated) Liposomes, Conventional Liposomes
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of ropivacaine in rib fracture (2 arms). Primary endpoint: Length of hospital stay at 7 days. Started Sep 2025; status: recruiting.
02
Drugs
ropivacaine
03
Conditions
rib fracture
Beyond the preview
Go deeper on NCT05642026.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05642026.